AF 353

Research use only, not for human use.

AF-353 is a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).

AF-353 is a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).

AF-353 (Ro-4) is a highly potent inhibitor of α,β-meATP-evoked intracellular calcium flux in cell lines expressing recombinant rat and human P2X3 and human P2X2/3 channels.AF-353 (Ro-4) also blocks human P2X2/3 channel function with marginally reduced potency with a p50 of 7.3.

AF-353 (Ro-4) does not compromise oxygen levels or cardiac function.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) inhibits the purinergic response in both normal and spinal cord-injured (SCI) rats.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) also reduces the inter-contractile interval in normal but not in SCI rats; however, the frequency of non-voiding (NVC) in SCI rats is significantly reduced. Animal Model:Female Sprague-Dawley rats (250–300 g) bearing SCI Dosage:10 mg/kg, 20 mg/kg Administration:Intravenous injection; interval of 90 minutes, for 4 hours to 6 hours Result:Significantly reduced purinergic response in both normal and SCI rats.

Ro-4

Neuroscience

P2 Receptor

P2X3

Cancer

——

865305-30-2

400.21

C14H17IN4O2

>98% (HPLC)

DMSO: 10 mM

NC1=NC=C(OC2=CC(I)=C(OC)C=C2C(C)C)C(N)=N1

5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine

(-20℃)

With Ice Pack

≥ 2 years